Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral, direct-acting, reversibly binding P2Y$_{12}$ receptor antagonist. It is part of a dual antiplatelet therapy (DAPT) regimen.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
* Reduction of new thrombotic cardiovascular events in patients with at least two prior myocardial infarctions, presenting with multiple cardiovascular risk factors.
## Adult Dosing
* **ACS:** A 180 mg loading dose is administered as soon as possible, followed by 90 mg twice daily.
* **Post-MI with multiple risk factors:** A 90 mg twice daily dose.
* **Maintenance after 1 year of DAPT for ACS:** Dosing may be reduced to 60 mg twice daily. The duration of DAPT should be individualized based on patient risk factors and bleeding risk.
## Pediatric Dosing
No established pediatric dosing.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is recommended in mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment needed for mild to moderate renal impairment. Data in severe renal impairment is limited, use with caution.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Major bleeding:** Including gastrointestinal and intracranial bleeding. The risk is increased in patients with prior bleeding events.
* **Dyspnea:** Often transient.
* **Ventricular pauses:** Particularly during sleep.
* **Bradycardia:**
* **Hyperuricemia and acute renal failure:**
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure. Concomitant use with strong inducers (e.g., rifampin, phenytoin) may decrease ticagrelor exposure.
* **CYP3A4 Substrates:** Ticagrelor can inhibit CYP3A4, potentially increasing the plasma concentration of drugs metabolized by this enzyme (e.g., simvastatin, atorvastatin). Avoid high-intensity statin therapy.
* **Aspirin:** Ticagrelor can potentiate the antiplatelet effect of aspirin.
* **Other Antithrombotics:** Increased risk of bleeding when used with other anticoagulants or antiplatelet agents.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Renal function:** Assess periodically, especially in patients with risk factors for renal impairment.
* **Uric acid levels:** Monitor periodically.
## Clinical Pearls
* Ticagrelor should be continued for at least 12 months in ACS patients, unless there is an increased bleeding risk or the patient is intolerant.
* Patients may experience dyspnea, which is often transient and not indicative of a cardiac event.
* Avoid concomitant use with P-glycoprotein inhibitors (e.g., cyclosporine).
* Ticagrelor can be taken with or without food.
* It is important to counsel patients on the signs of bleeding and when to seek medical attention.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols before making any clinical decisions.*
